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Abstract
The human immune system functions to provide continuous body-wide surveillance to detect and eliminate foreign agents
such as bacteria and viruses as well as the body’s own cells that undergo malignant transformation. To counteract this
surveillance, tumor cells evolve mechanisms to evade elimination by the immune system; this tumor immunoescape leads
to continuous tumor expansion, albeit potentially with a different composition of the tumor cell population
(‘‘immunoediting’’). Tumor immunoescape and immunoediting are products of an evolutionary process and are hence
driven by mutation and selection. Higher mutation rates allow cells to more rapidly acquire new phenotypes that help
evade the immune system, but also harbor the risk of an inability to maintain essential genome structure and functions,
thereby leading to an error catastrophe. In this paper, we designed a novel mathematical framework, based upon the
quasispecies model, to study the effects of tumor immunoediting and the evolution of (epi)genetic instability on the
abundance of tumor and immune system cells. We found that there exists an optimum number of tumor variants and an
optimum magnitude of mutation rates that maximize tumor progression despite an active immune response. Our findings
provide insights into the dynamics of tumorigenesis during immune system attacks and help guide the choice of treatment
strategies that best inhibit diverse tumor cell populations.
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Introduction
In 1909, Paul Ehrlich was the first to propose the idea that the
immune system scans for and eliminates nascent transformed cells
in the human body [1]. This hypothesis received much interest
from both immunologists and cancer researchers and led to
experiments with tumors transplanted into mice; these studies
suggested the existence of tumor-associated antigens and formed
the basis of the idea of immune surveillance [2]. Since these
landmark studies in the 1950s, the model of cancer immune
surveillance has gained widespread acceptance, and the central
role of immune effector cells, such as B, T, and natural killer (NK)
cells, have been elucidated [3,4,5,6,7]. NK cells and CD8z cd T
cells were found to recognize and kill tumor cells through the
interaction of specific cell surface receptors with tumor cell
ligands [3,8,9,10,11,12]. Similarly, CD4z and CD8z ab T cells
recognize MHC class II and class I molecules on tumor cells,
respectively, and B cells produce antibodies against tumor antigens
[3,6,13]. When the immune system fails to eliminate all tumor
cells, then the malignant cell population continues to grow – a
phenomenon termed ‘‘tumor immunoescape’’. The interaction
with the immune system, however, may significantly decimate the
abundance of tumor cells and select for those phenotypes with
relative resistance against immune system attacks. The ‘‘cancer
immunoediting’’ hypothesis then predicts that, while one outcome
is complete eradication of a developing tumor, another is the
generation of a sculpted tumor cell population that either displays
reduced immunogenicity [4] or an increased ability to inhibit anti-
tumor immune responses [6,14,15,16]. The latter capacity may be
imparted via diverse mechanisms [17,18]: (i) tumor cells can lose
their MHC class I molecules, enabling them to evade CTL attacks
[19]; (ii) while the immunodominant epitope becomes the main
target of immune responses, cells with other phenotypes may
continue proliferating in the ‘‘shadow’’ of the dominant clone [20];
(iii) furthermore, tumor cell secretion of immunosuppressive
cytokines such as TGF-b and IL-10 can reduce the efficiency of
the immune response [21], and (iv) a modification of death
signaling may prevent cells from undergoing apoptosis [22].
Tumor immunoescape is driven by the generation of tumor cell
variants [17,23]. Frequent genetic and epigenetic alterations
enable tumor cells to lose MHC class I molecules, produce
immunosuppressive cytokines, and generate other phenotypes that
are selected to escape immunosurveillance. Although cells with
normal rates of accumulating such alterations may also manage to
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evolution of genomic instabilities [24,25]. Genomic instabilities are
common in most cancer types [26], and two main categories have
been identified: in the majority of tumors, chromosomal insta-
bility (CIN) leads to an increased rate of losing or gaining whole
chromosomes or parts of chromosomes during cell division [24]; in
a smaller fraction of cancers, a mismatch-repair deficiency leads to
microsatellite instability (MIN) at the nucleotide level [27]. Similar
to genomic instabilities, epigenetic instabilities were also recently
found to contribute to tumorigenesis by modulating the produc-
tion of oncogenic proteins [28].
An increased chance of accumulating (epi)genetic alterations
during cell divisions enhances the rate of generating tumor cell
variants that may evade the immune response; however, high rates
of alterations may in turn lead to an error catastrophe in that a
functioning genome cannot be sustained when error-prone
replication produces excess damage [29]. The concept of an error
catastrophe was first introduced to describe the behavior of RNA
viruses [30], and numerous observations about the extinction of
such viruses due to excess error have been reported [31,32,33].
These findings imply that a mutator phenotype does not serve as
an unequivocal benefit for tumor cells, but also harbors a risk of
extinction if the extent of variability in the population crosses a
threshold. A delicate balance between the cost of a potential error
catastrophe and the benefits of outracing the immune response
enables tumor cells to survive and expand despite immune system
attacks.
Several mathematical models have been designed to provide
insights into the dynamics of tumorigenesis under immu-
nosurveillance or an error catastrophe of tumor cells
[34,35,36,37,38,39,40,41]. Most studies of the effects of immuno-
surveillance on tumor evolution considered a homogeneous
population of tumor cells and concentrated on phenomena such
as tumor dormancy and immunoescape. Studies of the tumor
error catastrophe, in contrast, investigated quasispecies models in
simplified situations without an immune response. The dynamics
of tumor immunoescape and error thresholds, however, result
from an interaction between both components; such studies are
still lacking from the literature. In this paper, we investigate an
integrated model of both concepts during tumor progression - the
effects of tumor immunosurveillance and the consequences of a
mutator phenotype of tumor cells. We introduce specific immune
responses to a formulation of the quasispecies model and study the
balance between evasion of immunosurveillance and prevention of
an error catastrophe. This study reveals the effects of various
tumor antigens on specific immune responses from the viewpoint
of evolutionary dynamics, and provides new perspectives on
optimum treatment strategies of tumors subjected to immunosur-
veillance and -editing.
Results
During the early phases of tumorigenesis, immune system cells
such as NK and CD8+ T cells attack tumor cells and may succeed
in suppressing their expansion; this outcome is referred to as
‘‘tumor dormancy’’. However, if the immune system cannot
successfully eradicate a tumor, then eventually a subset of tumor
cells will acquire the phenotypes necessary for immunoescape.
Depending on the magnitude of the mutation rate of these cells,
the tumor cell population may then be at risk of going extinct
due to the generation of excess damage – the event of an error
catastrophe. To investigate the dynamics, conditions, and
likelihood of these events, we designed a mathematical model of
tumor and immune system cells.
In the context of our mathematical model, initially there is only
a single type of tumor cells – those cells that originally founded the
tumor. Denote the abundance of these original tumor cells by x0.
They divide at rate f0 and die at rate d. During each division of
such a cell, a new variant tumor cell is produced with probability
u. Each tumor variant may have evolved a phenotype which
allows it to evade eradication by immune system cells. The
different tumor variants are enumerated as cell types i, and the
abundance of each type is given by xi. Let us first assume that
all tumor variants divide at rate a and die at rate d. These
assumptions ensure that intra-variant competition is stronger than
inter-variant competition, such that each tumor cell only competes
with cells of its own type for oxygen, nutrients, and space; these
assumptions will be relaxed later on. The total number of tumor
variants is denoted by N. Since we consider a maximum number
of N tumor variants, the growth rate of the original tumor cells
reduces to f0(1{Nu).
In addition to tumor cells, we also consider immune system cells
that launch a specific immune response against each particular
tumor variant. Denote the abundance of immune system cells
specific to the original tumor clone by y0, and the abundance of
those specific to tumor variant i by yi, for i~1,:::,N. These
immune system cells inhibit tumor variants at rate p and are
generated by interactions with the tumor cells at rate c. Figure 1
displays a schematic representation of this framework. Specific
immune responses such as CTLs recognize their target tumor
cells through random interactions and identification of antigens
presented on the cell surface [42,43]. In the context of the
mathematical model, we assume that immune system cells
encounter tumor cells at a rate proportional to the latter cells’
frequency, xi=(szX); the parameter s represents the coefficient of
interactions between immune and tumor cells, and X~
P
i xi
represents the total number of tumor cells. Expansion and
differentiation of specific immune responses (e.g., precursor CTL
proliferation and their differentiation into effector CTLs) are also
regulated through interactions with tumor cells [44]. Therefore,
Author Summary
Immunologic surveillance is a function of the immune
system which serves to constantly monitor the body for
microorganisms, foreign tissue, and cancer cells. To evade
this surveillance and subsequent elimination, cancer cells
evolve strategies to prevent being recognized and killed
by immune system cells; one mechanism is to increase the
rate at which genetic and/or epigenetic variability is
generated. The benefits of an increased variability of
cancer cells to counteract immune surveillance, however,
stands in contrast to the costs associated with such
heightened mutation rates: the risk of an inability to
maintain essential genome structure and functions. To
study such situations arising in tumorigenesis, we de-
signed a novel mathematical framework of tumor immu-
nosurveillance and the evolution of mutation rates. We
then utilized this framework to study how increased
mutation rates and immunologic surveillance affect the
abundance of tumor and immune system cells. We found
that there exists an optimum number of tumor variants
and an optimum magnitude of mutation rates that
maximize tumor progression despite the presence of
actively proliferating and functioning immune system
cells. Our study contributes to an understanding of cancer
development during immune system attacks and also
suggests treatment strategies for heterogeneous tumor
cell populations.
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CTLs are described in a frequency-dependent way, with maximum
elimination and proliferation rates of p and c, respectively. The
lifespan of CTLs is considered to be exponentially distributed with
mean 1=d days.
The basic mathematical model
With these considerations, we define the basic mathematical
model including tumor variants and their specific immune
responses by
x’0 ~f0(1{Nu)x0{
px0y0
szX
{dx2
0,
x’i ~f0ux0zaxi{
pxiyi
szX
{dx2
i fori~1,:::,N,
y’0 ~
cx0y0
szX
{dy0,
y’i ~
cxiyi
szX
{dyi fori~1,:::,N, and
X ~
P N
i~0
xi:
ð1Þ
Baseline values of model parameters and their respective ranges
used for simulations are presented in Table 1. A subset of these
parameter values were estimated in [39,45,46]. Since the original
tumor cell clone has been suggested to proliferate faster than
variant tumor cells [37,47], the division rate of variant tumor cells
is a~ef0 where 0vev1; we assume a default value of e~0:05 but
also perform sensitivity analyses (see a later section). We found
that, although some of these values are rough estimates and might
deviate when measured by other groups or in other systems, our
main results are qualitatively preserved within broad ranges
around our baseline values.
Let us now discuss the possible outcomes of interactions
between the immune system and the tumor cell population: there
may be tumor dormancy, partial immunoescape, complete
immunoescape, and the event of an error catastrophe. In the
dormancy state, immunosurveillance serves to effectively suppress
the tumor cell population. In the partial immunoescape state,
some tumor variants (but not all) achieve immunoescape while in
the complete immunoescape state, the immune response is
completely unsuccessful. Finally, in the error catastrophe state,
the original tumor clone, which has the highest division rate, goes
extinct due to the accumulation of excess alterations. We now
outline how the original tumor clone, the tumor cell variants, and
the specific immune system cells behave during the accumulation
of alterations and the evolution of higher mutation rates.
Tumor immunoescape and error catastrophe
The four qualitative outcomes of the interaction between tumor
cells and the immune system – dormancy, partial and complete
immunoescape as well as error catastrophe – are most significantly
influenced by two systems parameters: the mutation rate
generating tumor variants (u) and the maximum number of tumor
variant types that can emerge (N). We therefore investigated the
dynamics of tumor evolution in dependence of these parameters,
and identified three analytical thresholds (N 
1, N 
2, and N 
3)
separating the potential outcomes (Figure 2). The formulas and
detailed mathematical analyses of these thresholds are provided in
the Methods section.
As long as the number of tumor variants is less than the first
threshold, N 
1, immune responses suppress all tumor variants (tumor
dormancy). When the number of variants exceeds this threshold,
however, then some tumor cells escape from the specific immune
response (partial immunoescape). Once the number of variants passes
the second threshold, N 
2, all tumor cells escape from immune
responses (complete immunoescape). This finding implies that tumor
cells can evade immune surveillance by accumulating a sufficiently
large extent of intratumor heterogeneity. However, if the number of
variants exceeds the third threshold, N 
3,t h e na ne r r o rc a t a s t r o p h eo f
tumor cells occurs, in which the original tumor clone can no longer
maintain an expanding population and the original tumor cells
therefore go extinct. We also found that, as the mutation increases, the
threshold N 
1 increases while N 
2 and N 
3 decrease. In all scenarios,
however, tumor eradication is unlikely – although the tumor cell
burden may shrink by a large amount – when the growth rate of the
original tumor clone is negligibly small as compared to their death rate
by apoptosis and/or interactions with the immune system.
We have thus established that although high rates of
accumulating alterations allow tumor cells to reach a state of
complete immunoescape, those cells with an excessively high
mutation rate suffer an error catastrophe as the number of tumor
variant types increases. These systems dynamics suggest that there
is an optimum amount of instability that optimizes tumor
evolution (i.e. maximizes the number of tumor cells) while
maintaining a functioning genome.
Figure 1. A mathematical framework of tumor cell evolution
during immunosurveillance. The figure shows a schematic of the
mathematical model. Initially, there is only a single type of tumor cells –
those cells that originally founded the tumor. Their abundance is
denoted by x0; they divide at rate f0 and die at rate d. During each
division of such a cell, a new variant tumor cell is produced with
probability u. The tumor variants may have evolved a phenotype which
allows them to evade eradication by immune system cells. The different
tumor variants are enumerated as cell types i, and their abundances are
given by xi. Tumor variants divide at rate a and die at rate d. The total
number of tumor variant types is denoted by N. Since we consider N
tumor variant types, the growth rate of the original tumor cells reduces
to f0(1{Nu). In addition to tumor cells, we also consider immune
system cells that launch a specific immune response against each
particular tumor variant. Denote the abundance of immune system cells
specific to the original tumor clone by y0, and those specific to tumor
variant i by yi for i~1,:::,N. These immune system cells inhibit tumor
variants at rate p and are generated by interactions with the tumor cells
at rate c. Immune system cells encounter tumor cells at a rate
proportional to the latter cells’ frequency, xi=(szX); the parameter s
represents the coefficient of interactions between immune and tumor
cells, and X~
P
i xi represents the total number of tumor cells. The
lifespan of immune system cells is exponentially distributed with mean
1=d days.
doi:10.1371/journal.pcbi.1002370.g001
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Let us now investigate the system dynamics for varying
mutation rates and identify those regimes in which the total
tumor cell number is maximized. Every time a new tumor variant
arises, the dynamics of tumor evolution rapidly converges to its
steady state; we therefore analyze the dynamics in steady state. The
total number of tumor cells depends on the number of variants as
well as the mutation rate, and an optimum combination of these
parameter values exists that maximizes the total tumor cell number.
In Figure 3, we demonstrate how the total number of tumor cells is
affected by the number of tumor variant types for three different
cases in which the mutation rate is u~0:004, u~0:01,a n d
u~0:025, respectively. Detailed mathematical analyses of those
equilibria are provided in the Methods section.
Figure 2. The steady-state regime of tumor immunoescape and
error catastrophe. The figure displays the effects of the mutation rate
(u) and the maximum number of tumor variant types (N) on the
evolutionary dynamics of tumor cells. There are three thresholds that
determine the outcomes of interactions between immune system cells
and tumor cells. When the maximum number of tumor variant types is
less than N 
1, then immune responses suppress all tumor cells (blue),
but if the variant number exceeds this threshold, then tumor cells are
able to escape from their specific immune responses (yellow). Once the
number of tumor variants exceeds N 
2, all tumor cells completely
escape from immune responses (red). However, if their number exceeds
N 
3, then an error catastrophe occurs (gray) in which original tumor cells
cannot maintain a functioning genome due to excess error. Note that as
the mutation rate increases, the threshold N 
1 increases but N 
2 and N 
3
decrease. In situations of complete immunoescape (red), we obtain two
thresholds regarding the total number of tumor cells, Nc and uc. The
total number of tumor cells increases until the number of the variants
and the mutation rate, respectively, exceed Nc (dashed line) and uc
(dotted line), but then decreases after passing these thresholds.
doi:10.1371/journal.pcbi.1002370.g002
Figure 3. The total number of tumor cells during tumorigen-
esis. The figure displays the dynamics of the total number of tumor
cells during the generation of an increasing number of tumor variants.
In cases in which the dynamics are not stable, we show an average
number of tumor cells. The abbreviations D, PI, CI, and EC represent the
dormancy state, partial immunoescape state, complete immunoescape,
and error catastrophe, respectively. The solid, dashed, and dash-dotted
lines, respectively, represent mutation rates of u~0:004, 0:01 and 0:025.
The total number of tumor cells decreases once the number of tumor
variant types, N, exceeds a threshold Nc (for u~0:01 and 0:025) and
eventually suffers an error catastrophe as soon as the variant number
exceeds N 
3 (for u~0:025). Tumor cells with high mutation rates
increase in abundance by accumulating a large number of tumor
variant types during early phases of tumor progression, but are
incapable of efficient expansion in later phases due to the occurrence of
an error catastrophe.
doi:10.1371/journal.pcbi.1002370.g003
Table 1. Baseline parameter values and their ranges for numerical simulations.
Parameter Description (Units) Value and Range Reference
f0 Fitness of original cancer cells (day{1)5 :14:10{1 [39]
a Fitness of variant cancer cells (day{1) 2:5:10{2 [37,47]
d Degree of competition among variant cancer cells (cell
{1:day{1) 5:24:10{10 [39]
p Maximum elimination rate of cancer cells (day{1) 5.8 [39,41]
s Coefficient of interaction between CTL and cancer cells 2:0:107 [39]
c Maximum proliferation rate of CTLs (day{1) 3:75:10{2 [39]
d Decay rate of CTLs (day{1) 7:5:10{3 [46]
N Number of cancer variants [0,100] -
u Mutation rate of original cancer cells [0,0.05] -
doi:10.1371/journal.pcbi.1002370.t001
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suppressed by the immune response (tumor dormancy), the
total number of tumor cells increases with the number of
v a r i a n tt y p e s .I ns i t u a t i o n si nw h i c hs o m et u m o rc e l lt y p e s
manage to escape from immune surveillance, the total number
of tumor cells increases as both the number of variant types and
the mutation rate increase (Figure 3). However, in situations in
which all tumor cell types completely escape from their specific
immune responses, there exist two thresholds regarding the
total number of tumor cells: Nc and uc (see Figure 2). In this
scenario, the total number of tumor cells increases until the
number of variant types and the mutation rate, respectively,
exceed the values of Nc and uc; once crossing these thresholds,
the tumor cell number decreases as N and u further increase.
Therefore, tumor cells with an excessively high mutation rate
cannot continue to become more abundant as the number of
variant types increases (Figure 3), but there is an optimum, non-
trivial parameter regime that maximizes the number of tumor
cells.
Our results demonstrate that there are two strategies to
maximize the rate of tumor evolution so that the total tumor cell
mass is maximally large: one is to maintain a low mutation rate,
since then the tumor cell population can increase the number of
variant types along the threshold uc (see Figure 2); another is to
keep the number of variant types relatively small, since then the
tumor cell population can increase the mutation rate along the
threshold Nc (see Figure 2). When both the mutation rate and the
number of variant types are large, then the tumor cell population
cannot maintain its maximum number without decreasing one of
the two parameters.
Fitness of variant tumor cells
Let us now investigate how the division rate of variant tumor
cells affects the evolution of tumor cells during their interaction
with immune system cells. Recall that in the basic model, the
division rate is a~ef0, and that the threshold for an error
catastrophe to occur (N 
3) is independent of the division rate. To
investigate the dependence of the system behavior on this division
rate, we chose four different e and performed a sensitivity analysis
for the thresholds N 
1 and N 
2.
Figure 4 displays how the division rate of variant tumor cells
influences the outcome of tumor immunoescape in the plane of
mutation rates (u) and the number of tumor variants (N). The
four panels of the figure represent cases with different values of e.
The higher the fitness of variant tumor cells becomes, the more
easily they escape from immunosurveillance. However, the
qualitative profiles of the system dynamics are preserved; that
is, tumor cells with high mutation rates tend to reach a complete
immunoescape while tumor cells with low mutation rates
effectively produce a diverse population and thus increase in
number.
Extensions of the mathematical model
Let us next consider additional effects arising during tumor
progression such as competition among tumor cells of
different variant types, the presence of an innate immune
response such as NK cells, which non-specifically target all
tumor variants, and differential growth rates among tumor cell
variants. In order to investigate the conditions for outcomes
such as tumor immunoescape and error catastrophe in these
more complex scenarios, we established an extended model,
given by
x’0 ~f0(1{Nu)x0{
px0y0
szX
{
rx0z
szX
{dx0X,
x’i ~f0ux0zaixi{
pxiyi
szX
{
rxiz
szX
{dxiX,
y’0 ~
cx0y0
szX
{dy0,
y’i ~
cxiyi
szX
{dyi,
z’ ~sz
gXz
szX
{kz,
X ~x0z
P N
j~1
xj,
ð2Þ
where i~1,:::,N.T h ep a r a m e t e rai represents the division rate
of tumor variant i. We now assume that each tumor cell
competes with all other tumor cells so that the death term
becomes dxiX.F u r t h e r m o r e ,t h ev a r i a b l ez describes innate
immune responses, for instance by NK cells which attack
tumor cells without antigen specificity. The parameters g, r, k,
and s represent, respectively, the maximum proliferation rate
of NK cells, the maximum elimination rate of tumor cells by
NK cells, the decay rate of NK cells, and a constant source of
NK cells.
The dynamics of tumor progression considering these
situations are shown in Figure 5. We investigated how inter-
variant tumor cell competition (Figure 5A), incorporation of an
innate immune response (Figure 5B), growth rates which differ
between individual tumor variants (Figure 5C), and all three
effects simultaneously modulate the thresholds between
outcomes as well as the optimum parameter regimes for
maximizing tumor cell numbers. Competition among tumor
cells of the same variant type renders it difficult for the tumor
cell population to completely escape from immune surveillance
and to increase the total cell number beyond a relatively small
value, irrespective of the mutation rate (Figure 5A). However,
when only an innate immune response is present without inter-
variant competition, then there is a larger parameter regime in
which complete immunoescape is possible. Furthermore, the
total number of tumor cells is larger in this situation as
compared to the above case (Figure 5B). Similar to this scenario,
the presence of different growth rates for individual variant
clones allows for the existence of a large number of tumor cells
as well as a large regime in which complete immune escape can
be achieved (Figure 5C). Finally, when all three aspects are
combined in the mathematical model, then the region of
complete immune escape becomes very small; this effect is
mainly driven by the incorporation of interal competition. The
total number of tumor cells also remains below a rather small
threshold for this case (Figure 5D).
Optimum treatment strategies for diverse tumor cell
populations
Finally, let us discuss the effects of different treatment modalities
on the rates of cancer progression and the chance of immunoes-
cape. Since the behavior of tumor cells and thus patient outcomes
are to a considerable extent driven by the interactions between
tumor and immune system cells, we considered both traditional
chemotherapy and treatment options that stimulate the immune
system to launch or sustain an attack against the tumor cell
population. In general, immune therapies have not been proven
to be very effective against many tumor types; one of the few
exceptions is represented by adoptive cell therapy, which is used in
Tumor Immunoescape and Genome Maintenance
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about 50% of patients [48]. Recently, however, synergistic effects
of immunotherapy in combination with chemotherapy have been
reported in both human and animal trials [49,50,51], and several
mechanisms were identified that may explain these synergistic
effects [52].
To study the effects of chemotherapy, immune therapy, and
combination therapy on the dynamics of tumor evolution, we
introduced a series of different treatment types into the
mathematical framework and identified optimal treatment
strategies for diverse tumor cell populations (Figure 6). These
different treatment modalities were tested in situations in which
tumor cells had previously achieved complete immunoescape and
consisted of a large number of tumor cells. The number of tumor
variants and the mutation rate were considered to be N~50 and
u~0:01 at the time of treatment initiation. Chemotherapy then
reduces the number of tumor variants and kills tumor cells
proportional to the tumor cell number present. We also
Figure 4. The effects of change in the fitness of variant tumor cells. The figure displays how the fitness of variant tumor cells, a, affects the
dynamics of interactions between tumor and immune system cells. Parameters are (A) e~0:005, (B) 0:01, (C) 0:1, and (D) 0:25. As the fitness of variant
tumor cells increases, the parameter regime in which immunoescape is possible becomes larger; however, the qualitative behavior of the system
dynamics is preserved.
doi:10.1371/journal.pcbi.1002370.g004
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rate of tumor cells. Then the model after treatment initiation is
given by
x’0 ~f’0(1{N’u)x0{
px0y0
szX
{dx2
0{bx,
x’i ~f’0ux0za’xi{
pxiyi
szX
{dx2
i {bxi fori~1,:::,N’,
y’0 ~
cx0y0
szX
{dy0,
y’i ~
cxiyi
szX
{dyi fori~1,:::,N’, and
X ~
P N’
i~0
xi:
ð3Þ
Here chemotherapy reduces the number of tumor variants to N’
and either kills the tumor cells at rate b or reduces the growth
rates to f’0 and a’. Immunotherapy increases the number of
specific immune cells (yi for i~0,:::,N) during treatment.
We then utilized this system to investigate optimum treatment
strategies. First, let us consider the effects of chemotherapeutic
agents which reduce the number of tumor cells by inducing cell
deaths at a rate proportional to the cell number present within the
tumor. Administration of such treatments decreases the total
cell number, but may not be capable of leading to complete
eradication of all tumor cells (Figure 6A) unless its effects are
sufficiently (and maybe unrealistically) strong (Figure 6B). Second,
consider chemotherapeutic drugs which reduce the number of
tumor variant types as well as the growth rates of tumor cells.
Again, administration of such treatments decreases the total cell
number but is incapable of achieving complete eradication of
tumor cells (Figure 6C). Third, consider the administration of
immunotherapy which increases the population of tumor-specific
immune system cells. Such therapy alone is not able to decrease
the abundance of tumor cells by a large extent (Figure 6D).
However, when combining chemotherapy and immunotherapy,
an effective decrease of the tumor cell population can be achieved,
which may ultimately lead to tumor eradication and a cure
(Figure 6E). Notably, in situations in which the mutation rate is
small, the administration of combination therapy is more
successful in eradicating all tumor cells as compared to situations
in which the mutation rate is high (Figure 6F).
In conclusion, our mathematical model predicts successful
outcomes of combination therapy when (i) chemotherapy is
administered which induces tumor cell death at a significantly
large rate, or (ii) combination therapy is administered which
reduces the number of tumor variants, induces tumor cell death,
and replenishes immune cell populations. When the mutation rate
of tumor cells is small, combination therapy is more effective than
when variations arise at a large rate. An explanation of these
findings can be found in Figure 2 – activation of the immune
response alone does not change the state of the tumor cell
population once it has reached complete immunoescape; in that
case, the number of tumor cells does not decrease (Figure 6D). A
reduction of the number of tumor variant types and tumor
cells by administering chemotherapy alone allows for partial
immunoescape or dormancy states, but there is an insufficient
abundance of immune system cells to effectively control the tumor
cell population (Figure 6A). However, combination therapy which
enables immune cells to be activated in the states of partial
immunoescape or dormancy is capable of eradicating the tumor
(Figure 6E). Thus, our mathematical framework is capable of
identifying those treatment modalities that have the potential to
lead to a cure of the tumor.
Discussion
In this paper, we have investigated the dynamics of tumor
progression under immune system surveillance while considering
the effects of increasing rates at which (epi)genetic alterations are
generated. We defined specific situations that can arise due to the
interactions of immune system cells and tumor cells. When the
tumor cell population is able to persist under immunosurveillance
without leading to tumor growth, then a state of tumor dormancy
ensues. Should the immune system not be capable of efficiently
suppressing the tumor cell population, then partial or complete
immunoescape is possible, depending on whether some or all
tumor clones evade immune system inhibition. Finally, an error
catastrophe occurs when the tumor cells evolve mutation rates that
are incompatible with the maintenance of a functioning genome
due to excess error.
The dynamics of the system and likelihood of these different
states depend on the rate at which variability emerges in the
population (denoted by the mutation rate u per cell division) as
well as the number of distinct tumor clones (given by N) that are
distinguished by their capabilities of generating a specific immune
response (see Figure 2). If both quantities are excessively large,
then an error catastrophe occurs and the original tumor cell
population goes extinct. In intermediate regimes, states of
dormancy and partial or complete immunoescape are possible.
We also investigated the extent to which the total number of tumor
cells depends on these parameters and identified regimes in which
the maximum number of tumor cells is attained. Moreover, we
relaxed the model assumptions to consider more complex
scenarios such as growth competition among tumor variants,
innate immune responses that non-specifically recognize and kill
tumor cells, and different growth rates of tumor variants. These
studies revealed that the patterns of states do not vary significantly
as the assumptions of competition, growth, and innate immune
responses are altered; however, internal competition among tumor
variants renders it difficult for tumor cells to achieve complete
immune escape.
Finally, we investigated the effects of different treatment modalities
on the rates of tumor progression and found that administration of
both chemotherapy and immunotherapy leads to optimum response
rates, thereby confirming recent experimental findings [49,50,51].
These investigations have direct implications for the clinical
management of cancers since they incorporate both mutator
phenotype and the interactions between tumor cells and the immune
system. A consideration of these factors is essential for an
understanding of the dynamics of tumor cell populations evolving
during immune system attacks. Our results thus suggest that
Figure 5. More complex scenarios arising during tumor progression. The figure displays the effects of more complex situations arising during
tumorigenesis such as internal competition between tumor cells of different variant types (A), the presence of an innate immune response such as NK
cells,which inhibitall tumor cells equally (B), different growth rates of tumor variants (C), andall of the above (D). These factors areincorporated into the
basic model, equation (1). The qualitative behavior of the system is preserved although the size and identity of the parameter regimes for various
outcomes are different. Additional parameters in the extended models are (B) g~0:025, r~0:000000323, k~0:0412 and s~13000, (C) variant growth
rates ai are randomly sampled from a normal distribution with mean=0:025 and variance=0:01, and (D) all of the above.
doi:10.1371/journal.pcbi.1002370.g005
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PLoS Computational Biology | www.ploscompbiol.org 8 February 2012 | Volume 8 | Issue 2 | e1002370Figure 6. Optimal treatment strategies. The figure displays the effects of several treatment modalities on the total tumor burden. Treatment
starts at time t~0. The number of tumor variant types and the mutation rate are given by N~50 and u~0:01. We consider situations in which tumor
cell populations have reached the state of complete immunoescape before the initiation of therapy. (A and B) Chemotherapy is administered which
reduces the number of tumor variant types and induces tumor cell deaths proportional to the tumor cell number. (C) Chemotherapy is administered
which reduces the number of variant types and the growth rates of tumor cells. (D) Immunotherapy is used which replenishes the number of tumor-
specific immune cells. (E and F) Chemotherapy and immunotherapy are administered which reduce the number of tumor variant types, induce tumor
cell deaths, and replenish specific immune cells. Parameters are (A) 10% of tumor cells are killed per time unit by chemotherapy (b~0:1) and the
number of tumor variants decreases to N’~50 (red), N’~40 (yellow), N’~30 (green), N’~20 (blue), and N’~10 (purple); (B) the number of tumor
variants does not change (N’~50), but 10% (red), 20% (yellow), 30% (green), 40% (blue), and 50% (purple) of tumor cells are killed by chemotherapy;
(C) growth rates are reduced by 10% by chemotherapy and the number of tumor variants decreases to N’~50 (red), N’~40 (yellow), N’~30 (green),
N’~20 (blue), and N’~10 (purple); (D) 1 (red), 100 (yellow), and 10,000 (green) immune cells specific to each tumor variant are added into the
system by the administration of immunotherapy; (E) 10,000 immune cells specific to each tumor variant are added into the system by
immunotherapy, 10% of tumor cells are killed per time unit by chemotherapy, and the number of tumor variants decreases to N’~50 (red), N’~40
(yellow), N’~30 (green), N’~20 (blue), and N’~10 (purple) by chemotherapy; and (F) 10000 immune cells specific to each tumor variant are added
into the system by the administration of immunotherapy, 10% of tumor cells are killed per time unit by chemotherapy, the number of tumor variants
does not change (N’~50), and mutation rates are u~0:01 (red), u~0:05 (yellow), and u~0:1 (green).
doi:10.1371/journal.pcbi.1002370.g006
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immunostimulatory agents would lead to best results in the clinic.
Our mathematical framework represents only one possibility of
modeling the system of tumor and immune system cells. This
modeling choice was made for reasons of mathematical simplicity
as well as availability of parameter estimates; however, several
model extensions are conceivable. For instance, the spatial
components of the system could be incorporated such that the
spatio-temporal aspects can be considered. Also, we have neglected
stochasticity in our formulation of the mathematical model since
both population sizes and mutation rates are large, and therefore
deterministic dynamics dominate. However, for more detailed
investigations – such as a determination of the probability that a
certain phenotype arises – the stochasticity of the system cannot be
neglected. Such studies will be the topic of future contributions.
Furthermore, interactions with the microenvironment such as with
stromal cells and other factors could be considered. The
incorporation of these extensions are complicated by the fact that
few quantitative estimates are available. The determination of
system parameters necessary for including such factors into a
mathematical framework is an important goal of the field.
Methods
Mathematical analysis
Let us first consider the basic model, equation (1), in detail. The
basic model can be considered qualitatively as a 4-dimensional
ODE system (although equation (1) is a 2(Nz1)-dimensional
ODE system) when analyzing the equilibria, since all parameters
in the equations describing xi and yi are the same, and therefore
xi and yi have the same properties at the equilibria. Hence we can
consider that X~x0zNxi with respect to the equilibria, where N
is a model parameter.
Existence conditions of equilibria
We investigated the existence conditions of the equilibria of
model (1). The model has seven possible equilibria:
E0 ~(0,0,0,0);
Ee ~(0,xi
_
,0,0) where xi
_
~
a
d
;
Ec ~(~ x x0,~ x xi,0,0) where ~ x x0~
f0(1{Nu)
d
and
~ x xi~
az
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
a2z4f 2
0 (1{Nu)u
q
2d
;
En ~(0, ’ xi ,0, ’ yi ) where ’ xi ~
ds
c{dN
and
’ yi ~
(a{d ’ xi )(szN ’ xi )
p
;
Eu ~(^ x x0,^ x xi,0,^ y yi) where ^ x x0~
f0(1{Nu)
d
and
^ x xi~
dfdszf0(1{Nu)g
d(c{dN)
,
^ y yi ~
(f0u^ x x0za^ x xi{d^ x x2
i )(sz^ x x0zN^ x xi)
p^ x xi
;
Ep ~(  x x0,  x xi,  y y0,0) where   x x0~
d(szN  x xi)
c{d
,
  y y0~
c(szN  x xi)
p(c{d)
f0(1{Nu){
dd(szN  x xi)
c{d
  
,
and   x xi is the positive root of the following equation:
F(xi)~d(c{d)  x x2
i {fa(c{d)zf0dNug  x xi{f0dsu~0;
Ez ~(xz
0 ,xz
i ,yz
0 ,yz
i ) where xz
0 ~xz
i ~
ds
c{(Nz1)d
,
yz
0 ~
cs
pfc{(Nz1)dg
|
f0(1{Nu){
dds
c{(Nz1)d
  
, and
yz
i ~
cs
pfc{(Nz1)dg
f0uza{
dds
c{(Nz1)d
  
;
While the equilibria E0 and Ee always exist, Ec only exists if
Nv1=u. Furthermore, En exists if Nvc=d{ds=a,a n dEu exists if
Nv1=u, Nvc=d and f0u^ x x0za^ x xi{d^ x x2
i w0 because c{dw0. The
existence condition of Ep is ff0(1{Nu)(c{d){ddsg=ddNw  x xi.I n
addition, we calculate the existence conditions of Ez as follows.
Note that xz
0 ~xz
i w0 and yz
i w0 are equivalent to Nv(c{d)=d
and Nv(c{d)=d{ds=(azf0u), respectively. If Nv(c{d)=d,
then we have the following relations:
yz
0 w0 uf0(1{Nu){
dds
c{(Nz1)d
w0
uG(N)~f0duN2{f0fu(c{d)zdgNzf0(c{d){ddsw0,
because G(1=u)v0, G(N)~0 always has real roots Nc and   N Nc
(Ncv  N Nc). Here we assume that f0(c{d){ddsw0: otherwise Ez
never exists and Ec becomes stable. Therefore, yz
0 w0 is equivalent
to NvNc. Note that the roots of G(N)jd~0~0 are (c{d)=d and
1=u, which implies that Ncv(c{d)=d,1 =u. Furthermore,
when u~0, G(N)w0 is equivalent to Nv(c{d)=d{ds=f0.
Since (c{d)=d{ds=av(c{d)=d{ds=f0 in the context of f0wa
(which is a suitable assumption), we can roughly estimate that
(c{d)=d{ds=(azf0u)vNc if uvv1. Consequently, if
Nv(c{d)=d{ds=(azf0U), f0(c{d){ddsw0, f0wa and
uvv1,t h e nEz exists.
Derivation of thresholds
Consider the situation in which Ez exists, all tumor cells are
suppressed by their specific immune responses, and the number of
tumor variants is 1 (i.e., N~1). Let us investigate the transversal
eigenvalue in the yi{direction at Ep. Here we define
N 
1~
c{d
d
{
ds
azf0u
:
Since sz  x x0zN  x xi~c  x x0=d, the transversal eigenvalue is evaluated
as follows:
Ly’i
Lyi
v0 u
c  x xi
sz  x x0zN  x xi
{dv0
u
  x xi
  x x0
{1
  
dv0
u  x xiv
ds
c{d(Nz1)
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ds
c{d(Nz1)
  
w0
u
sd(c{d)½ff0(Nz1)uzdsgd{cf0uzafd(Nz1){cg 
fc{(Nz1)dg
2 w0
uff0(Nz1)uzdsgd{cf0uzafd(Nz1){cgw0
uN 
1vN:
This result implies that, if N 
1vN, then Ez disappears from R
4
z
and yi approaches 0 near Ep. Hence only the original tumor cells
are suppressed by their specific immune responses while tumor
variants escape from immune surveillance once the number of
tumor variant exceeds N 
1. Next, we investigate the transversal
eigenvalue in the y0{direction at Ec. Here we define N 
2 to satisfy
f0(1{N 
2u)(c{d){dds
ddN 
2
~  x xi(N 
2):
The transversal eigenvalue is evaluated as follows:
Ly0
0
Ly0
v0 u
c~ x x0
sz~ x x0zN~ x xi
{dv0
u c~ x x0v(sz~ x x0zN~ x xi)d
u 2(c{d)f0(1{Nu){d(2dszaN)
vdN
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
a2z4f 2
0 (1{Nu)u
q
u f2(c{d)f0(1{Nu){d(2dszaN)g
2
vd
2N2fa2z4f 2
0 (1{Nu)ug
u 4Sc2f 2
0 (Nu{1)
2{cf0(Nu{1)f2f0(Nu{1){aN{2dsgd
z½f 2
0 f1{2NuzN2(u{1)uzN3u2gzds(aNzds)
{f0(Nu{1)(aNz2ds) d
2Tv0:
On the other hand, we have the following relations:
N 
2vN u
f0(c{d)(1{Nu){dds
ddN
v
a(c{d)zf0duNz
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
fa(c{d)zf0duNg
2z4(c{d)f0udds
q
2d(c{d)
u2(1{Nu)f0(c{d)
2{d(c{d)(aNz2ds){f0ud
2N2
vdN
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
fa(c{d)zf0duNg
2z4(c{d)df0dsu
q
uf2(1{Nu)f0(c{d)
2{d(c{d)(aNz2ds){f0ud
2N2g
2
vd
2N2½fa(c{d)zf0duNg
2z4(c{d)df0dsu 
u4(c{d)
2Sc2f 2
0 (Nu{1)
2{cf0(Nu{1)f2f0(uN{1){aN{2dsgd
z½f 2
0 f1{2NuzN2(u{1)uzN3u2gzds(aNzds)
{f0(Nu{1)(aNz2ds) d
2Tv0:
This result implies that N 
2vN is equivalent to Ly’0=Ly0v0 near
Ec;t h a ti s ,i fN 
2vN,t h e nEp disappears from R
4
z and y0 converges
to 0 near Ec (Ec is stable). Thus, the immune response against the
original tumor clone also becomes inactivated if the number of tumor
variants exceeds N 
2.Note that we consider a restricted region of u and
N,w h e r e2(1{Nu)f0(c{d)
2{d(c{d)(aNz2ds){f0ud
2N2w0.
Consequently, all tumor cells escape from their immune responses
once the number of tumor variants exceeds N 
2.F u r t h e r m o r e ,t h e
original tumor cell clone is no longer sustainable (i.e., an error
catastrophe occurs) as soon as the number of the variants exceeds
N 
3~1=u.
The total number of tumor cells
Let us now calculate the total number of tumor cells at
equilibrium. Note that the dynamics of the basic model, equation
(1), might not converge to an equilibrium, but may oscillate if
NvN 
2.
When the number of tumor variants is 0vNvN 
1, then the total
number of tumor cells at Ez is Xz~(Nz1)ds=fc{(Nz1)dg.
Since we evaluate LXz=LNw0 and LXz=Lu~0, the total number
of tumor cells increases as the number of variants grows. When the
number of variants is N 
1vNvN 
2, then the total number of tumor
cells at Ep is   X X~(cN  x xizds)=(c{d). Again, as we evaluate
L  X X=LNw0 and L  X X=Luw0, the total number increases as the
number of variants and the mutation rate increase. When the
number of variants is N 
2vNvN 
3, then the total number of tumor
cells at Ec is ~ X X~f2f0(1{Nu)zaNzN
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
a2z4f 2
0 (1{Nu)u
q
g=2d.
Here we find critical thresholds Nc and uc suchasL~ X X=LNjN~Nc~0
and L~ X X=Luju~uc~0. Therefore, the total number of tumor cells
increases as long as the number of variants and the mutation rate
are N 
3vNvNc and uvuc, respectively. However, once the
number of variants and the mutation rate exceed Nc and uc,
respectively, the total number of tumor cells decreases. Eventually,
when the number of variants is N 
3vN, the total number of tumor
cells at Ee is Xe~aN=d.
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